Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
90.9M
-
Shares change
-
+10M
-
Total reported value, excl. options
-
$4.62B
-
Value change
-
+$518M
-
Put/Call ratio
-
1.13
-
Number of buys
-
123
-
Number of sells
-
-82
-
Price
-
$50.81
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q1 2022
255 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q1 2022.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.9M shares
of 125M outstanding shares and own 72.65% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (14.2M shares), Avoro Capital Advisors LLC (9.45M shares), VANGUARD GROUP INC (8.57M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.88M shares), BlackRock Inc. (5.92M shares), EcoR1 Capital, LLC (5.18M shares), STATE STREET CORP (2.91M shares), JENNISON ASSOCIATES LLC (2.7M shares), Octagon Capital Advisors LP (2.34M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.49M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.